ETR:MDG1

Medigene - MDG1 Stock Forecast, Price & News

€2.24

-0.04 (-1.75%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: €2.22
▼
€2.27
50-Day Range: €1.89
▼
€2.42
52-Week Range: €1.75
▼
€4.59

Volume: 2,013 shs
Average Volume: 306,207 shs
Market Capitalization: $55.02 million

P/E Ratio: 5.74
Dividend Yield: N/A
Price Target: N/A

About Medigene (ETR:MDG1) Stock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

November 15, 2022 | finance.yahoo.com

Medigene Announces Strategy and Corporate Update

November 7, 2022 | finance.yahoo.com

Are Strong Financial Prospects The Force That Is Driving The Momentum In Medigene AG's ETR:MDG1) Stock?

August 5, 2022 | finance.yahoo.com

Medigene AG (MDG1.DE)

February 21, 2022 | finance.yahoo.com

BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer

March 20, 2021 | finanznachrichten.de

PTA-News: Medigene AG: Veränderung im Vorstand

August 16, 2020 | uk.finance.yahoo.com

MEDIGENE AG MEDIGENE K ORD SHS (0QGJ.IL)

June 23, 2020 | finance.yahoo.com

Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

June 22, 2020 | www.benzinga.com

Medigene's PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors

June 22, 2020 | finance.yahoo.com

Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors

May 29, 2020 | finance.yahoo.com

PHIO: Intasyl Advantage vs. Gene Editing

April 9, 2020 | finance.yahoo.com

Analysts Are Betting On Medigene AG (ETR:MDG1) With A Big Upgrade This Week

March 31, 2020 | finance.yahoo.com

Did You Manage To Avoid Medigene's (ETR:MDG1) Painful 67% Share Price Drop?

March 31, 2020 | finance.yahoo.com

Did You Manage To Avoid Medigene's (ETR:MDG1) Painful 67% Share Price Drop?

March 28, 2020 | finance.yahoo.com

MEDIGENE AG NA O.N. (MDG1.DU)

March 26, 2020 | finance.yahoo.com

Medigene Provides Results for Fiscal Year 2019 and Outlook

January 30, 2020 | www.benzinga.com

IRICoR, Université de Montréal and Medigene sign collaboration and exclusive licensing option on novel cancer antigens

January 29, 2020 | finance.yahoo.com

Medigene, IRICoR and Université de Montréal Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens

January 20, 2020 | finance.yahoo.com

Does Medigene AG's (ETR:MDG1) CEO Pay Reflect Performance?

January 10, 2020 | finance.yahoo.com

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

January 1, 2020 | www.barrons.com

MediGene AG

November 18, 2019 | finance.yahoo.com

Medigene AG Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

November 13, 2019 | finance.yahoo.com

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

November 13, 2019 | finance.yahoo.com

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

August 8, 2019 | markets.businessinsider.com

Medigene H1 Net Loss Widens; Backs FY19 Outlook - Quick Facts

April 22, 2019 | finance.yahoo.com

PHIO: Activation in the Tumor Microenvironment

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ETR
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ETR:MDG1
CUSIP: N/A
CIK: N/A
Web: www.medigene.de
Phone: +49-89-2000330
Fax: N/A
Employees: 58
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 5.74
Forward P/E Ratio: N/A
P/E Growth: 7.12
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 6.31
Current Ratio: 6.04
Quick Ratio: 5.85

Sales & Book Value

Annual Sales: $31.46 million
Price / Sales: 1.75
Cash Flow: €1.55 per share
Price / Cash Flow: 1.45
Book Value: €2.41 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 24,562,700
Free Float: N/A
Market Cap: $55.02 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Dolores J. Schendel
Chief Scientific Officer, Member of Exec. Management Board and Head of R&D

Dr. Selwyn Ho MB BS (Age 51)
MBBS, CEO & Member of Exec. Management Board

Dr. Ernst-Ludwig Winnacker (Age 81)
Co-Founder & Chairman Scientific Advisory Board

Dr. Birger Kohlert
Chief Financial Officer

Dr. Anna Niedl
VP Investor Relations & Corp. Communications

Dr. Rene Goedkoop
Acting Chief Medical Officer

Key Competitors

View All Competitors

MDG1 Stock - Frequently Asked Questions

How have MDG1 shares performed in 2022?: Medigene's stock was trading at €2.87 at the beginning of 2022. Since then, MDG1 shares have decreased by 21.8% and is now trading at €2.24.
View the best growth stocks for 2022 here.
What other stocks do shareholders of Medigene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP).

What is Medigene's stock symbol?: Medigene trades on the ETR under the ticker symbol "MDG1."
What is Medigene's stock price today?: One share of MDG1 stock can currently be purchased for approximately €2.24.
How much money does Medigene make?: Medigene (ETR:MDG1) has a market capitalization of $55.02 million and generates $31.46 million in revenue each year.
How can I contact Medigene?: Medigene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The official website for the company is www.medigene.de. The company can be reached via phone at +49-89-2000330.

This page (ETR:MDG1) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial